While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...

Novo Nordisk has potential with a 27% upside, strong market shares, and high ROI strategies. See why we recommend a buy on ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

Ever since the pharmaceutical company Novo Nordisk realized that GLP-1 drugs were useful for more than diabetes, doctors and ...

Injected weight-loss drugs Wegovy, from Novo Nordisk, and Eli Lilly's Zepbound have U.S. list prices of over $1,000 a month.

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

As a Biden administration ban on so-called “junk fees” took effect Monday, Ticketmaster said it would start displaying the ...

Wall Street’s bets that the US-China trade truce marked the end to an all-out tariff war drove the S&P 500 up 3%, while ...

A new study found users of one drug lost almost 50 percent more weight that users of Wegovy. People taking Eli Lilly’s ...